The concentrated selling by a single director over five days is notable but not alarming at 0.11% of market cap. Monitor for any upcoming earnings release or clinical data readout that could explain the timing.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $17.41entry
- T+1 · 7mo ago +0.80%α −0.22% · $17.55
- T+5 · 7mo ago +8.21%α +5.10% · $18.84
- T+20 · 6mo ago +6.61%α +0.56% · $18.56
- T+60 · 4mo ago +40.38%α +36.27% · $24.44
Price Chart
How similar events traded
Executive Summary
Director Jason P. Rhodes sold $3.4M worth of DYN shares over a five-day window, with total insider selling of $3.4M representing 0.11% of the $3.0B market cap. While the dollar amount is modest relative to market cap, the concentrated selling by a single director at an average price of ~$18.80 (near recent highs) suggests potential profit-taking ahead of a catalyst or uncertainty.
Key Financial Metrics
Key Facts
- Director Jason P. Rhodes sold 177,181 shares total across 4 open-market sales from April 22-27, 2026, for ~$3.36M
- Director Dirk Kersten sold 2,652 shares on April 22 for ~$53K
- Director David Charles Lubner gifted 53,625 shares on April 24 (non-cash, $0 value)
- Total open-market selling value: ~$3.42M, representing 0.11% of DYN's $3.0B market cap
Financial Impact
Total insider selling of $3.42M, or 0.11% of market cap, modest relative to company size
Risk Factors
- Director Rhodes sold near recent highs (~$18.80 avg), which could indicate insider concern about valuation or upcoming news
- No insider buying in the cluster to offset selling, one-sided selling pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1777409838174 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers